Safety, Tolerability, and Pharmacokinetics of Intravenous Doses of PF‐07304814, a Phosphate Prodrug Protease Inhibitor for the Treatment of SARS‐CoV‐2, in Healthy Adult Participants-Reference-Cited by-同舟云学术

Safety, Tolerability, and Pharmacokinetics of Intravenous Doses of PF‐07304814, a Phosphate Prodrug Protease Inhibitor for the Treatment of SARS‐CoV‐2, in Healthy Adult Participants

Published:2022-10-26 Issue:12 Volume:11 Page:1382-1393
ISSN:2160-763X
Container-title:Clinical Pharmacology in Drug Development
language:en
Short-container-title:Clinical Pharm in Drug Dev

Author:

Zhu Tong¹,Pawlak Sylvester²,Toussi Sima S.³,Hackman Frances⁴,Thompson Kimberly²,Song Wei⁵,Salageanu Joanne⁶,Winter Erica⁶,Shi Haihong⁶,Winton Jennifer⁶,Binks Michael¹

Affiliation:

1. Pfizer Worldwide Research Development and Medical Cambridge Massachusetts USA

2. Pfizer Clinical Research Unit New Haven Connecticut USA

3. Pfizer Worldwide Research Development and Medical, Pearl River New York USA

4. Pfizer Worldwide Research Development and Medical Cambridge UK

5. Pfizer Worldwide Research Development and Medical Groton Connecticut USA

6. Pfizer Global Product Development Groton Connecticut USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmaceutical Science

Link